The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

Molzym was founded as a privately owned enterprise in Bremen, North-West Germany, in 2003. Ever since, Molzym has been committed to the development of innovative solutions to serve biological research and diagnosis of infectious diseases. Our developmental efforts are particularly focused on new processes enabling and facilitating the molecular diagnosis of infectious diseases caused by bacteria and fungi. Meanwhile, more than 50 high quality products are available for molecular microbial analysis by PCR-, hybridization- and NGS-based methods in 30 countries worldwide.

PathogenDx has developed a microarray based test specifically designed for the cannabis, botanical, food and agricultural testing markets. Our technology allows test labs to conduct between 12- 48 tests in parallel, testing up to 20 pathogens per test in less than a days’ shift. This is done at a fraction of the cost of plate counts or Realtime PCR. Our Raw Sample technology allows laboratories to bypass almost 20 steps that Real-time PCR must perform for DNA extraction and purification. PathogenDx technology bypasses the need for purification, quantitation, and normalization increasing the speed and affordability of pathogen screening. This helps our customers reduce testing time by 12 hours on the front end, and avoid spending money on sample prep kits and additional instrumentation.

DermTech develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. The Company’s assays can analyze multiple gene targets to assess their level of RNA expression. The Company anticipates providing these assays through a CLIA certified laboratory located in San Diego. The Company will initially offer an assay for pigmented skin lesions sampled using an adhesive tape collection method. The Company has identified gene targets differentially expressed in melanoma samples (British Journal of Dermatology, April 2011). This assay can assess RNA expression consistent with melanoma with very high sensitivity (>95%) and specificity (>70%).

MycoDART Inc., is the developer of molecular diagnostic tests for the rapid detection of deadly infections in very vulnerable patients such as transplant, cancer, and AIDS. Their team has dozens of years experience in business management, laboratory operations, and molecular diagnostics development. They are in the pre-launch stage for MycoDART-PCR Candida Panel. This test will identify Invasive Candidiasis infections earlier and with higher reliability than the current standard of care. As such, it will reduce mortality and cost of treatment for thousands of patients. A panel for Invasive Aspergillosis will follow.

The Research Institute at Nationwide Children's Hospital is one of America's ten largest free-standing pediatric research centers and works to enhance the health of children by engaging in research.

Nippon Paper Group is a diversified international timber, pulp, paper, paperboard packaging and chemicals business with operations in Asia, Oceania, North and South America and Europe. Headquartered in Tokyo, Japan, Nippon Paper was founded in 1949 and is listed on the Tokyo Stock Exchange with net sales of approx. $15 billion AUD. Nippon Paper Group is committed to global expansion through its key growth areas of packaging, household paper and healthcare, chemicals, energy, and wood products. Past acquisitions have included Australian Paper in 2009 for approx. $700 million AUD and the Weyerhaeuser liquid packaging board business in 2016 for $285 million USD. The purchase of Orora's Australasian Fibre Packaging business will be the Group's largest investment outside Japan.

Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN.

DuPont offers sustainable solutions for agriculture, electronics, communications, construction, transportation, and apparel markets. Their products and services include construction materials, fabrics, packaging materials, medical devices, electronic solutions, and adhesives for markets. They provide specialized construction materials to create and maintain roads, bridges, telecommunications, power, and water plants.

Jiangsu King's Luck Brewery Joint-stock Co., Ltd. engages in the manufacture and sale of distilled spirit wine. It also offers pre-package food. The company was founded on December 23, 1997 and is headquartered in Huaian, China.

At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.

Antu Experimental Instrument (Zhengzhou) Co., Ltd., established on 2007-03-15, Business scope includes medical devices,electronic product,Mechanical equipment and accessories,Research and development of experimental consumables,Production,Sales,Consulting and Services;Research and development of computer software, hardware and network technology,Consulting and Services;road general cargo transportation;Warehousing Services(Excluding flammable and explosive hazardous chemicals);Import and export of goods or technology;Production and sales of computer software and hardware.

WinField Solutions LLC manufactures and distributes seed and crop protection products for growers, dealers, and other industrial customers. It offers adjuvants, dyes and wetting agents, granular and liquid micronutrients, plant nutrients, turf seeds, crop seeds, grain protectants, seed treatment products, fertilizers, herbicides, insecticides, fungicides, pest control products, and other products to farmers for planning, planting, in-season shifting, and harvesting. The company is headquartered in Shoreview, MN.

Microbe Detectives provides DNA analysis of aquatic microbiomes to mitigate risks of water-related diseases and reduce costs.

Genex Corp. is an American private company located in Palatine, IL, that provides electrical services.

Shenzhen Haisi En Technology Co., Ltd., established on 2014-10-17, Business scope includes general business items:electronic product development;Domestic Trade;Import and export of goods and technology;Computer software and hardware services;Business information consultation;Own house rental.(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating),The licensing program is:Warehousing Services;electronics production.

John Wayne Cancer Institute is a private company headquartered in Santa Monica, CA, that operates cancer research institute.\nThe company says this about itself: Since 1981, the family of John Wayne has been committed to pioneering cancer research in memory of their father, who died of cancer. The courageous and dedicated researchers at the John Wayne Cancer Institute have made groundbreaking discoveries that have changed the way cancer is detected, diagnosed and treated around the world. Today the tradition of excellence continues as the Institute spearheads new research advances, while training the next generation of leaders in the fight against cancer through its renowned Surgical Oncology Fellowship Program. The Institute provides immediate hope to cancer patients everywhere.